Results
eNauka >
Rezultati >
Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial
| Naziv: | Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial | Autori  : | Reck, Martin; ...; Andric, Zoran G   ; ...; (broj, koautora 18) |
Godina: | 2024 | Publikacija: | JOURNAL OF THORACIC ONCOLOGY | ISSN: | 1556-0864 Journal of Thoracic Oncology Pretraži identifikator |
Tip rezultata: | Naučni članak | Kolacija: | vol. 19 br. 2 str. 297-313 | DOI: | 10.1016/j.jtho.2023.09.1445 | WoS-ID: | 001176202400001 | Scopus-ID: | 2-s2.0-85176396741 | URI: | https://enauka.gov.rs/handle/123456789/938672 | Projekat: | Healthcare business of Merck KGaA, Darmstadt, Germany Pfizer |
Izvor metapodataka: | (Preuzeto iz Nasi u WoS) | M-kategorija: | 21a+M21a+ - Vodeći međunarodni časopis kategorije M21a+ |
Items in eNauka are protected by copyright, with all rights reserved, unless otherwise indicated.